Literature DB >> 16951383

Gliadin-specific type 1 regulatory T cells from the intestinal mucosa of treated celiac patients inhibit pathogenic T cells.

Carmen Gianfrani1, Megan K Levings, Claudia Sartirana, Giuseppe Mazzarella, Gianvincenzo Barba, Delia Zanzi, Alessandra Camarca, Gaetano Iaquinto, Nicola Giardullo, Salvatore Auricchio, Riccardo Troncone, Maria-Grazia Roncarolo.   

Abstract

Celiac disease (CD) results from a permanent intolerance to dietary gluten and is due to a massive T cell-mediated immune response to gliadin, the main component of gluten. In this disease, the regulation of immune responses to dietary gliadin is altered. Herein, we investigated whether IL-10 could modulate anti-gliadin immune responses and whether gliadin-specific type 1 regulatory T (Tr1) cells could be isolated from the intestinal mucosa of CD patients in remission. Short-term T cell lines were generated from jejunal biopsies, either freshly processed or cultured ex vivo with gliadin in the presence or absence of IL-10. Ex vivo stimulation of CD biopsies with gliadin in the presence of IL-10 resulted in suppression of Ag-specific proliferation and cytokine production, indicating that pathogenic T cells are susceptible to IL-10-mediated immune regulation. T cell clones generated from intestinal T cell lines were tested for gliadin specificity by cytokine production and proliferative responses. The majority of gliadin-specific T cell clones had a Th0 cytokine production profile with secretion of IL-2, IL-4, IFN-gamma, and IL-10 and proliferated in response to gliadin. Tr1 cell clones were also isolated. These Tr1 cells were anergic, restricted by DQ2 (a CD-associated HLA), and produced IL-10 and IFN-gamma, but little or no IL-2 or IL-4 upon activation with gliadin or polyclonal stimuli. Importantly, gliadin-specific Tr1 cell clones suppressed proliferation of pathogenic Th0 cells. In conclusion, dietary Ag-specific Tr1 cells are present in the human intestinal mucosa, and strategies to boost their numbers and/or function may offer new therapeutic opportunities to restore gut homeostasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16951383     DOI: 10.4049/jimmunol.177.6.4178

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

Review 1.  Celiac disease in pediatric patients with autoimmune hepatitis: etiology, diagnosis, and management.

Authors:  Fabio Panetta; Valerio Nobili; Maria Rita Sartorelli; Raffaele Edo Papa; Francesca Ferretti; Arianna Alterio; Antonella Diamanti
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

Review 2.  Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers.

Authors:  Megan E Himmel; Yu Yao; Paul C Orban; Theodore S Steiner; Megan K Levings
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

3.  Induction of antigen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo Dq8 transgenic mice.

Authors:  Inge L Huibregtse; Eric V Marietta; Shadi Rashtak; Frits Koning; Pieter Rottiers; Chella S David; Sander J H van Deventer; Joseph A Murray
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

Review 4.  Effector and suppressor T cells in celiac disease.

Authors:  Giuseppe Mazzarella
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

5.  Regulatory T Cells: Concept, Classification, Phenotype, and Biological Characteristics.

Authors:  Yang Du; Qiannan Fang; Song-Guo Zheng
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  The roles of MHC class II genes and post-translational modification in celiac disease.

Authors:  Ludvig M Sollid
Journal:  Immunogenetics       Date:  2017-07-10       Impact factor: 2.846

7.  Selected Probiotic Lactobacilli Have the Capacity To Hydrolyze Gluten Peptides during Simulated Gastrointestinal Digestion.

Authors:  Ruggiero Francavilla; Maria De Angelis; Carlo Giuseppe Rizzello; Noemi Cavallo; Fabio Dal Bello; Marco Gobbetti
Journal:  Appl Environ Microbiol       Date:  2017-06-30       Impact factor: 4.792

8.  Intestinal T cell responses to gluten peptides are largely heterogeneous: implications for a peptide-based therapy in celiac disease.

Authors:  Alessandra Camarca; Robert P Anderson; Gianfranco Mamone; Olga Fierro; Angelo Facchiano; Susan Costantini; Delia Zanzi; John Sidney; Salvatore Auricchio; Alessandro Sette; Riccardo Troncone; Carmen Gianfrani
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

9.  In vitro differentiation of human monocytes into dendritic cells by peptic-tryptic digest of gliadin is independent of genetic predisposition and the presence of celiac disease.

Authors:  Maryam Rakhimova; Birgit Esslinger; Anja Schulze-Krebs; Eckhart G Hahn; Detlef Schuppan; Walburga Dieterich
Journal:  J Clin Immunol       Date:  2008-08-12       Impact factor: 8.317

10.  Small intestinal CD8+TCRgammadelta+NKG2A+ intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease.

Authors:  Govind Bhagat; Afzal J Naiyer; Jayesh G Shah; Jason Harper; Bana Jabri; Timothy C Wang; Peter H R Green; John S Manavalan
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.